Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

COEP Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Coeptis Therapeutics, Inc.NASDAQ: COEP

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 60.3%

Gross margin was 60.3% in Q1 FY2026, up 32.1 pp from a year earlier. On a trailing-twelve-month basis it was 87.2%, up 59.0 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
60.3%-34.5 pp QoQ
Last fiscal yearDec 2025
86.7%— YoY
LTMMar 2026
87.2%+59.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+32.1 pp——
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
86.7%
Year-over-year change
—

Gross Margin vs competitors

How COEP compares with its peers on the latest reported figures

  • COEP's LTM Mar 2026 gross margin of 87.2% is the 4th highest of the 6 companies compared; the peer median is 88.0%.
  • Its year-over-year change of +59.0 pp is the highest of 5, against a peer median of -6.1 pp.
COEP Competitors Peer median
Gross Margin for COEP and competitors
Company Period LTM level YoY 3-year change
CUECue Biopharma, Inc.LTM Mar 202699.8% -0.2 pp+0.0 pp
KPTIKaryopharm Therapeutics Inc.LTM Mar 202696.0% -0.1 pp-0.8 pp
IPSCCentury Therapeutics, Inc.FY202588.0% -12.0 pp-12.0 pp
COEPCoeptis Therapeutics, Inc.LTM Mar 202687.2% +59.0 pp—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202637.1% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-360.9% -377.1 pp—
EQEquillium, Inc.FY2025— ——
OSTXOS Therapies IncorporatedFY2025— ——
TELOTelomir Pharmaceuticals, Inc. Common StockFY2025— ——
Peer median (excluding COEP) 88.0%-6.1 pp-0.8 pp

Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75K0001.36M
Cost of Revenue0000180.63K
Gross Profit75K0001.18M
Gross Margin100.0%———86.7%
Research & Development020.89K6.67M2.33M1.28M
Selling, General & Admin14.12M34.18M13.82M6.72M11.95M
Operating Expenses14.12M34.2M21.49M10.05M14.23M
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
EBITDA(12.81M)(36.35M)(20.12M)(9.38M)(10.41M)
EBITDA Margin-17086.3%———-763.9%
Operating Income(14.05M)(34.2M)(21.49M)(10.05M)(13.04M)
Operating Margin-18727.9%———-956.9%
Interest Income0000116.5K
Interest Expense187.13K218.41K107.69K396.12K642.38K
Other Income / Expenses596.65K(3.38M)224.59K(822.92K)766.31K
Income Before Tax(13.45M)(37.57M)(21.27M)(10.88M)(12.28M)
Pre-Tax Margin-17932.4%———-900.7%
Income Tax Expense00000
Net Income(13.45M)(37.57M)(21.27M)(10.68M)(11.92M)
Net Margin-17932.4%———-874.3%
EPS (Basic)(13.16)(2.87)(0.83)(5.65)(2.81)
EPS (Diluted)(13.16)(2.87)(0.83)(5.65)(2.81)
Weighted Avg Shares1.02M14.3M25.69M1.93M4.23M
Weighted Avg Shares (Diluted)1.02M14.3M25.69M1.93M4.23M

Coeptis Therapeutics, Inc.

NASDAQ:COEP

Intrinsic Alpha fair value

Locked

Current Price

$14.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.